- Home
- YGMZ vs CTSO Comparison
YGMZ vs CTSO Comparison
Compare YGMZ & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- CTSO
- Stock Information
- Founded
- YGMZ 2002
- CTSO 1997
- Country
- YGMZ China
- CTSO United States
- Employees
- YGMZ N/A
- CTSO N/A
- Industry
- YGMZ Transportation Services
- CTSO Medical/Dental Instruments
- Sector
- YGMZ Consumer Discretionary
- CTSO Health Care
- Exchange
- YGMZ Nasdaq
- CTSO Nasdaq
- Market Cap
- YGMZ 57.6M
- CTSO 61.7M
- IPO Year
- YGMZ 2020
- CTSO N/A
- Fundamental
- Price
- YGMZ $0.73
- CTSO $0.93
- Analyst Decision
- YGMZ
- CTSO Buy
- Analyst Count
- YGMZ 0
- CTSO 2
- Target Price
- YGMZ N/A
- CTSO $5.50
- AVG Volume (30 Days)
- YGMZ 206.5K
- CTSO 98.2K
- Earning Date
- YGMZ 01-01-0001
- CTSO 11-06-2025
- Dividend Yield
- YGMZ N/A
- CTSO N/A
- EPS Growth
- YGMZ N/A
- CTSO N/A
- EPS
- YGMZ N/A
- CTSO N/A
- Revenue
- YGMZ $40,429,750.00
- CTSO $36,107,520.00
- Revenue This Year
- YGMZ N/A
- CTSO $11.93
- Revenue Next Year
- YGMZ N/A
- CTSO $21.22
- P/E Ratio
- YGMZ N/A
- CTSO N/A
- Revenue Growth
- YGMZ N/A
- CTSO 20.18
- 52 Week Low
- YGMZ $0.63
- CTSO $0.71
- 52 Week High
- YGMZ $1.77
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- YGMZ 43.73
- CTSO 46.42
- Support Level
- YGMZ $0.73
- CTSO $0.87
- Resistance Level
- YGMZ $0.85
- CTSO $1.04
- Average True Range (ATR)
- YGMZ 0.13
- CTSO 0.05
- MACD
- YGMZ -0.02
- CTSO -0.00
- Stochastic Oscillator
- YGMZ 11.17
- CTSO 38.45
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.